Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | PDE2A | O00408 | 6/20 | 0.40 |
| ▸ | KRAS | P01116 | 3/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25453738 | 1.00 | SPR (0.44) | SPRCNR2USP30PDE2AKRAS | |
| SCHEMBL23901500 | 0.89 | SPR (0.54) | SPRCNR2USP30 | |
| SCHEMBL23901474 | 0.85 | SPR (0.48) | SPRCNR2USP30PDE2AKRAS | |
| SCHEMBL23901483 | 0.77 | USP30 (0.45) | SPRCNR2USP30KRASP2RX7 | |
| SCHEMBL14413642 | 0.73 | USP30 (0.54) | CNR2USP30PDE2ARIPK1 | |
| SCHEMBL1710753 | 0.73 | USP30 (0.50) | USP30PDE2A | |
| SCHEMBL25454990 | 0.72 | GLRA1 (0.46) | SPR | |
| SCHEMBL25453440 | 0.72 | USP30 (0.54) | CNR2USP30PDE2ARIPK1 | |
| SCHEMBL19049384 | 0.72 | USP30 (0.54) | CNR2USP30PDE2ARIPK1 | |
| SCHEMBL25455849 | 0.72 | SPR (0.39) | SPRCNR2USP30KRASP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | HAVCR2, CD44, ENGASE | SPR 931/4885CNR2 4767/4885USP30 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.